TS
CERE

Thomas Steyer’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Thomas Steyer’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,190,000
Closed -$48.7M – 184
2024
Q2 		$48.7M Buy
1,190,000
+127,000
+12% +$5.29M 0.21% 60
2024
Q1 		$44.9M Buy
1,063,000
+495,679
+87% +$20.8M 0.19% 59
2023
Q4 		$24.1M Buy
+567,321
New +$16.3M 0.11% 66

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Thomas Steyer's CERE Position: Q3 2024 in Review

Thomas Steyer sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,190,000 shares — an estimated $48.7M sold.

Thomas Steyer first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $48.7M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Thomas Steyer reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Thomas Steyer sold 1,190,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $48.7M.
  • Thomas Steyer first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Thomas Steyer's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $48.7M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.